Corcept Therapeutics CORT Accrued liabilities
Accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccruedLiabilities.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Corcept Therapeutics's accrued liabilities?
- Corcept Therapeutics (CORT) reported accrued liabilities of -$9.38M in Q1 2026.
- How has Corcept Therapeutics's accrued liabilities changed year-over-year?
- Corcept Therapeutics's accrued liabilities decreased by 59.7% year-over-year, from -$5.87M to -$9.38M.
- What is the long-term trend for Corcept Therapeutics's accrued liabilities?
- Over 2 years (2021 to 2024), Corcept Therapeutics's accrued liabilities has grown at a 146.8% compound annual growth rate (CAGR), from $6.48M to $39.45M.